Neogen Corp.

As of August 12, 2025, Neogen Corp. shows a mildly bearish technical trend with mixed signals from various indicators, significantly underperforming the S&P 500 year-to-date and over the past year.

As of July 30, 2024, Neogen Corp. is considered overvalued and risky, with a high P/E ratio of 281, a low Price to Book Value of 0.42, and poor performance reflected in a YTD return of -53.29% and a 10Y return of -84.97%, significantly underperforming compared to its peers and the S&P 500.

As of June 18, 2025, Neogen Corp. is in a bearish trend with moderate strength, supported by bearish monthly indicators and daily moving averages, despite some mixed signals from the KST and MACD.

As of July 30, 2024, Neogen Corp. is considered overvalued with a risky valuation grade, highlighted by a P/E ratio of 281, poor financial performance with a ROCE of 1.61% and ROE of 0.15%, and a significant year-to-date stock decline of 60.71% compared to a 2.44% gain for the S&P 500.

As of March 2022, Neogen Corp.'s management team includes CEO John Adent and Lead Independent Chairman James Borel, along with several independent directors: Dr. William Boehm, Dr. Ronald Green, Mr. G. Bruce Papesh, Mr. James Tobin, and Ms. Darci Vetter.

Neogen Corp. develops and markets products for food and animal safety within the Pharmaceuticals & Biotechnology industry. As of February 2025, it has net sales of $221 million, a net profit of -$11 million, and a market cap of approximately $1.15 billion.

As of Jun 18, Neogen Corp. has a market capitalization of 1,145.96 million, classifying it as a Small Cap company, with net sales of 905.99 million and a net profit of -485.27 million over the latest four quarters.